Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Ongoing and future clinical studies are expected to provide deeper insights into its mechanisms of action and expand its therapeutic applications
Proc Nat Acad Sci
Previous reports demonstrated that HMGB1 interacted with CRM1 for active export from nuclear (7D), whereas, overexpression of GSTP substantially attenuated interaction between HMGB1 and CRM1
A 2025 IV safety study (Lee & Burgess, Alternative Therapies / PubMed) administered up to 20 mg IV in healthy adults with no adverse events recorded across cardiac, hepatic, renal, and thyroid biomarkers
US$ 27.57
US$ 20.57
US$ 27.34
